ProCE Banner Activity

Population-Based Assessment of Socioeconomic Treatment Inequities With Biomarker-Guided Targeted Therapy and Immunotherapy for Patients With NSCLC

Slideset Download
Conference Coverage
In a retrospective analysis of a publicly funded healthcare setting, patients with NSCLC and greater socioeconomic deprivation were less likely to receive novel therapy such as targeted therapies, biologics, and immunotherapies.

Released: August 17, 2022

Expiration: August 16, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc